Trevena Reports Positive Phase 1 Results For TRV734 For Acute And Chronic Pain

(RTTNews) - Trevena Inc. (TRVN) announced positive results from its Phase 1 trial of TRV734, which the company is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids.

The study tested single ascending doses and the relative bioavailability of oral TRV734 in healthy subjects, and demonstrated that TRV734 is pharmacologically active at a range of safe and well-tolerated doses.

The company said the data suggested that TRV734 provides dose-related exposure, speed of onset, and duration of action suitable for treating moderate-to-severe acute pain.

Highlights of the two-part trial involving a total of 76 healthy subjects include: Dose-related increases in plasma concentrations, with peak plasma concentrations reached approximately one hour after dosing and a terminal half life consistent with use for treating acute pain; Pupil constriction indicative of analgesia observed at doses of 80 mg and higher, and mild-to-moderate adverse effects reported at the maximum explored dose of 250 mg. This suggests that the analgesic efficacy of TRV734 may be separable from opioid-related adverse effects; No clinically significant changes in vital signs, laboratory values or ECG parameters, and no severe or serious adverse events reported.